Navigation Links
Circulating tumor cells predicted recurrence, death in patients with early-stage breast cancer
Date:12/10/2010

SAN ANTONIO The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment.

Results of this study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010, and demonstrate the value of CTCs in early breast cancer, independent of estrogen-receptor or HER2 status and before use of adjuvant therapy.

The benefit of using CTCs to predict risk for recurrence and death in metastatic breast cancer patients has been shown in a number of studies, and use of a CTC test in metastatic breast cancer has been approved by the Food and Drug Administration.

The CTCs found in this study are likely evidence that a tumor is shedding breast cancer cells, said lead researcher Brigitte Rack, M.D., head of the department of gynecological oncology at the Women's Hospital at the University of Munich, Germany. "The CTCs might have been released from the primary tumor before these patients underwent surgery, and the expression of stem cell markers on disseminated tumors cells has been shown by several groups."

Survival of these CTCs after chemotherapy further suggests they are cancer stem cells, Rack added.

Researchers with this study are testing the effectiveness of two different chemotherapy regimens and extended adjuvant bisphosphonate treatment in early breast cancer. SUCCESS' efficacy data are expected to be released next year.

Results of this study showed that 21.5 percent of patients had one or more CTC in their blood before the start of adjuvant treatment. These patients were more frequently node-positive, but no other linkage could be made with tumor size or grade or HER2 status.

Breast cancer recurred in 114 patients, and 66 patients died. Being CTC-positive was a significant independent predictor for both disease-free and overall survival. Patients with one to four CTCs had an 88 percent increased risk of early breast cancer recurrence and a 91 percent increased risk of death from breast cancer, according to Rack.

Prognosis was worse in patients with five or more CTCs; these patients had a fourfold risk of cancer recurrence and a threefold risk for death from the disease.

"Our study suggests testing CTCs may prove to be important to help individualize therapy for early-stage breast cancer where no measurable tumor is present," she said. "Patients who seem to be at high risk due to CTC may benefit from additional treatment options, and those that don't have CTCs may be spared side effects of some treatments."

She added, however, that prospectively randomized trials are necessary to show an improvement of survival based on CTC diagnostics. Trials testing this notion are either ongoing or about to start in Europe and the United States, according to Rack.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Poor breast cancer prognosis associated with presence of circulating tumor, cancer stem cells
2. Circulating tumor cells can provide real-time information on patients current disease state
3. Circulating tumor cells correlate with poorer survival in pancreatic cancer patients
4. Survival in metastatic breast cancer directly linked to circulating tumor cells
5. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
6. Revisiting the need to detect circulating tumor cells
7. A double block of blood vessels to starve cancerous tumors
8. Protein targeted to stop melanoma tumor growth
9. Tumors bring their own support cells when forming metastases
10. New prostate cancer imaging shows real-time tumor metabolism
11. Researchers shine light on how some melanoma tumors evade drug treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... Melbourne, FL (PRWEB) , ... May 28, 2017 ... ... Partners of America (PPOA), is proud to announce that Jorge Fernandez-Silva, M.D., has ... comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques to ...
(Date:5/27/2017)... ... May 27, 2017 , ... Hate visiting the dentist? You should go twice per year ... care of your teeth at home. Here are some dental tips to help out: , ... small toothbrush in your work desk or a locker at school for a quick brushing ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to announce ... in USA Today, which will educate readers on how to take care of all ... large focus is placed on melanoma. Dancing with the Stars professional, Witney Carson, shares ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s Algovita® ... Algovita SCS System has been FDA approved as a treatment option for chronic intractable ... the most powerful SCS system and the only stretchable lead on the market. This ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for ... applications. “We are thrilled to partner with Cupron® to provide customers with ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017 Hologic, Inc. (Nasdaq: ... the fiscal second quarter ended April 1, 2017 . ... increased 666.7% compared to the prior year period as ... a significant gain, while non-GAAP diluted EPS of $0.50 ... 3.8% in constant currency terms.  Excluding the effects of ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
Breaking Medicine Technology: